|
Study of ABI-007 and Taxol in Patients with Metastatic Breast Cancer Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Study of ABI-007 and Taxol in Patients with Metastatic Breast Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Study of ABI-007 and Taxol in Patients with Metastatic Breast Cancer Clinical research trials and Study of ABI-007 and Taxol in Patients with Metastatic Breast Cancer healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Study of ABI-007 and Taxol in Patients with Metastatic Breast Cancer. Study of ABI-007 and Taxol in Patients with Metastatic Breast Cancer Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Study of ABI-007 and Taxol in Patients with Metastatic Breast Cancer clinical trial. Human subjects often obtain the finest healthcare possible for their Study of ABI-007 and Taxol in Patients with Metastatic Breast Cancer condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of ABI-007 and Taxol in Patients with Metastatic Breast Cancer  Study of ABI-007 and Taxol in Patients with Metastatic Breast Cancer
Study of ABI-007 and Taxol in Patients with Metastatic Breast Cancer
For Condition: Breast Neoplasms,Metastases, Neoplasm
Status: No longer recruiting
Sponsor(s): American Bioscience ,
Synopsis: Paclitaxel (Taxol, Bristol-Meyers Squibb) has been shown to be very effective against metastatic breast cancer, as well as other cancers. Because the Taxol formulation of paclitaxel is dissolved in Cremophor, an organic solvent containing castor oil, and ethanol, prolonged intravenous administration times are required; and because the solvent has caused hypersensitivity reactions, a premedication schedule is required. ABI-007 is a new anticancer medication containing the same active ingredient as Taxol, paclitaxel, but formulated as a protein-stabilized material that is suspended in salt water and administered intravenously. The time of administration is reduced, the dose of paclitaxel can be higher than is safe for Taxol, and there is no premedication required. This study will determine the efficacy of this new formulation of paclitaxel, as compared to Taxol, for patients with metastatic breast cancer. This is an open label comparative study, so patients will be randomly assigned to receive either the Taxol or ABI-007 forms of paclitaxel, but will know what medication they are receiving. Treatment will be repeated every three weeks unless adverse events or treatment failure require discontinuing study medication.
Details: Taxol (Bristol-Meyers Squibb) is active against carcinomas of the ovary, breast, lung, esophagus and head and neck. A number of dose schedules of Taxol have been tested in breast cancer. Initial trials used 250 mg/m2 as a continuous infusion over 24 hours. Subsequently, shorter infusions of Taxol over three hours were tested at a dose of 175 mg/m2, with response rates of 30%-40%. Phase II studies using higher doses of Taxol at 200-250 mg/m2 had a response rate of 56% in metastatic breast cancer patients. However, at these doses, significant toxicities occurred, including neuropathy. There was a median granulocyte count nadir at 100-200 cells/mm3 for the majority of courses administered. There were also significant side effects associated with hypersensitivity to the Taxol vehicle, Cremophor-EL. These hypersensitivity reactions require a premedication schedule that includes a corticosteroid, an H2 antagonist and an antihistamine. American Bioscience is testing a reformulated form of paclitaxel without Cremophor. This formulation is a protein-stabilized, nanoparticle suspension of paclitaxel and human serum albumin in normal saline. The potential advantages of this formulation are: - Higher tolerated doses, with greater efficacy - Longer drug persistence in tumor as a result of the nanoparticle formulation - Reduced infusion time - Reduced risk of hypersensitivity with no required premedication schedule - More rapid distribution of paclitaxel to the tissues based on pharmacokinetic data This study will evaluate ABI-007, as compared to Taxol, in patients with metastatic breast cancer.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 16 Years/
Genders: Both
Protocol Entry Criteria: Patients will be eligible for this trial if: - Female, non-pregnant, non-lactating, and, if of child-bearing potential, have a negative serum pregnancy test, and use approved contraception - Sixteen years of age or older - Histologically or cytologically confirmed breast cancer (stage III or IV) with evidence of inoperable local recurrence or metastasis, with measurable disease - If patient has received taxane therapy as an adjuvant he/she has not relapsed within one year of completing adjuvant taxane - No other malignancy present within the past 5 years, except non-melanoma skin cancer, cervical intraepithelial neoplasia or in-situ cervical cancer - Suitable candidate for paclitaxel therapy - Hematology levels at baseline of: absolute neutrophil count of at least 1500 cells/mm3; platelet count of at least 100,000 cells/mm3; hemoglobin of at least 9 g/dL - Chemistry levels at baseline of: AST and ALT of less than or equal to 2.5 x the upper limit of normal, if no evidence of liver metastasis; total bilirubin of less than or equal to 1.5 mg/dL; creatinine of less than or equal to 2 mg/dL; alkaline phosphatase of less than or equal to 5 x the upper limit of normal, unless there is bone metastasis but not liver metastasis - Expected survival of at least 12 weeks - Patient or his/her representative has signed an informed consent form
Total Enrollment: 460
Location and Contact Information:
Overall Study Official:
MichaelHawkins, Study Director, American Bioscience, Inc.
American Bioscience, Inc
Raleigh, North Carolina, 27609
United States
Additional Information:
Study ID Numbers: CA012-0;
Study Start Date: June 2001
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00046527
Other Breast Neoplasms Studies:
1. Women's Health Initiative (WHI)
2. Outcomes of Education and Counseling for BRCA1 Testing
3. An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen.
4. A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy with G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients
5. An investigational drug (CAL) versus zoledronic acid (Zometa®) in patients with breast cancer
Related Studies:
Other Breast Neoplasms Clinical Trials
Other North Carolina Clinical Trials
Other Raleigh Clinical Trials
Study of ABI-007 and Taxol in Patients with Metastatic Breast Cancer
|
|
|
|
|
|
|
|
